Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry
Braz. j. infect. dis
;
12(3): 198-201, June 2008. tab
Artículo
en Inglés
| LILACS
| ID: lil-493647
ABSTRACT
Tigecycline is the first of a new class of antibiotics named glycylcyclines and it was approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. Notwithstanding this, tigecycline's pharmacological and microbiological profile which includes multidrug-resistant pathogens encourages physicians' use of the drug in other infections. We analyzed, during the first months after its launch, the tigecycline prescriptions for 113 patients in 12 institutions. Twenty-five patients (22 percent) received tigecycline for approved indications, and 88 (78 percent) for "off label" indications (56 percent with scientific support and 22 percent with limited or without any scientific support). The most frequent "off label" use was ventilator associated pneumonia (VAP) (63 patients). The etiology of infections was established in 105 patients (93 percent). MDR-Acinetobacter spp. was the microorganism most frequently isolated (50 percent of the cases). Overall, attending physicians reported clinical success in 86 of the 113 patients (76 percent). Our study shows that the "off label" use of tigecycline is frequent, especially in VAP. due to MDR-Acinetobacter spp., where the therapeutic options are limited (eg: colistin). Physicians must evaluate the benefits/risks of using this antibiotic for indications that lack rigorous scientific support.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Infecciones Bacterianas
/
Minociclina
/
Antibacterianos
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
/
Factores de riesgo
Límite:
Adolescente
/
Adulto
/
Anciano
/
Aged80
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2008
Tipo del documento:
Artículo
País de afiliación:
Argentina
/
Chile
Institución/País de afiliación:
CEMIC/AR
/
Center of Research in Infectious Diseases/AR
/
Clínica Ciudad/AR
/
Clínica San Camilo/AR
/
FLENI Instituto de Investigaciones Dr.Raúl Carrea/AR
/
Hospital Dr. Eduardo Castro Rendón/AR
/
Hospital Español/AR
/
Hospital Italiano/AR
/
Hospital Ramos Mejía/AR
/
Instituto Cardiovascular de Buenos Aires/AR
Similares
MEDLINE
...
LILACS
LIS